Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up

Roger Hagen; Odin Hjemdal; Stian Solem; Leif Kennair; Hans M. Nordahl; Peter Fisher; Adrian Wells

doi:10.3389/fpsyg.2017.00031

Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up

Roger Hagen, Odin Hjemdal, Stian Solem, Leif Kennair, Hans M. Nordahl, Peter Fisher, Adrian Wells

Division of Psychology & Mental Health (L5)

Research output: Contribution to journal › Article › peer-review

292 Downloads (Pure)

Abstract

This randomized controlled trial examines the efficacy of metacognitive therapy (MCT) for depression. Thirty-nine patients with depression were randomly assigned to immediate
MCT (10 sessions) or a 10-week wait list period (WL). The WL-group received 10 sessions of MCT after the waiting period. Two participants dropped out from WL and none dropped out of immediate MCT treatment. Participants receiving MCT improved
significantly more than the WL group. Large controlled effect sizes were observed for both depressive (d = 2.51) and anxious symptoms (d = 1.92). Approximately 70–80% could be classified as recovered at post-treatment and 6 months follow-up following immediate MCT, whilst 5% of the WL patients recovered during the waiting period. The results suggest that MCT is a promising treatment for depression. Future controlled
studies should compare MCT with other active treatments.

Original language	English
Pages (from-to)	1-10
Number of pages	11
Journal	Frontiers in Psychology
Volume	8
DOIs	https://doi.org/10.3389/fpsyg.2017.00031
Publication status	Published - 24 Jan 2017

Access to Document

10.3389/fpsyg.2017.00031

Frontiers 2017_depressionFinal published version, 867 KB

Cite this

@article{9d88148823844507987200519f364c51,

title = "Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up",

abstract = "This randomized controlled trial examines the efficacy of metacognitive therapy (MCT) for depression. Thirty-nine patients with depression were randomly assigned to immediateMCT (10 sessions) or a 10-week wait list period (WL). The WL-group received 10 sessions of MCT after the waiting period. Two participants dropped out from WL and none dropped out of immediate MCT treatment. Participants receiving MCT improvedsignificantly more than the WL group. Large controlled effect sizes were observed for both depressive (d = 2.51) and anxious symptoms (d = 1.92). Approximately 70–80% could be classified as recovered at post-treatment and 6 months follow-up following immediate MCT, whilst 5% of the WL patients recovered during the waiting period. The results suggest that MCT is a promising treatment for depression. Future controlledstudies should compare MCT with other active treatments.",

author = "Roger Hagen and Odin Hjemdal and Stian Solem and Leif Kennair and Nordahl, {Hans M.} and Peter Fisher and Adrian Wells",

year = "2017",

month = jan,

day = "24",

doi = "10.3389/fpsyg.2017.00031",

language = "English",

volume = "8",

pages = "1--10",

journal = "Frontiers in Psychology",

issn = "1664-1078",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up

AU - Hagen, Roger

AU - Hjemdal, Odin

AU - Solem, Stian

AU - Kennair, Leif

AU - Nordahl, Hans M.

AU - Fisher, Peter

AU - Wells, Adrian

PY - 2017/1/24

Y1 - 2017/1/24

N2 - This randomized controlled trial examines the efficacy of metacognitive therapy (MCT) for depression. Thirty-nine patients with depression were randomly assigned to immediateMCT (10 sessions) or a 10-week wait list period (WL). The WL-group received 10 sessions of MCT after the waiting period. Two participants dropped out from WL and none dropped out of immediate MCT treatment. Participants receiving MCT improvedsignificantly more than the WL group. Large controlled effect sizes were observed for both depressive (d = 2.51) and anxious symptoms (d = 1.92). Approximately 70–80% could be classified as recovered at post-treatment and 6 months follow-up following immediate MCT, whilst 5% of the WL patients recovered during the waiting period. The results suggest that MCT is a promising treatment for depression. Future controlledstudies should compare MCT with other active treatments.

AB - This randomized controlled trial examines the efficacy of metacognitive therapy (MCT) for depression. Thirty-nine patients with depression were randomly assigned to immediateMCT (10 sessions) or a 10-week wait list period (WL). The WL-group received 10 sessions of MCT after the waiting period. Two participants dropped out from WL and none dropped out of immediate MCT treatment. Participants receiving MCT improvedsignificantly more than the WL group. Large controlled effect sizes were observed for both depressive (d = 2.51) and anxious symptoms (d = 1.92). Approximately 70–80% could be classified as recovered at post-treatment and 6 months follow-up following immediate MCT, whilst 5% of the WL patients recovered during the waiting period. The results suggest that MCT is a promising treatment for depression. Future controlledstudies should compare MCT with other active treatments.

U2 - 10.3389/fpsyg.2017.00031

DO - 10.3389/fpsyg.2017.00031

M3 - Article

SN - 1664-1078

VL - 8

SP - 1

EP - 10

JO - Frontiers in Psychology

JF - Frontiers in Psychology

ER -

Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up

Abstract

Access to Document

Fingerprint

Cite this